💧 Prefilled Syringe Container Closure

Why Prefilled Syringes Need Silicone — Engineering Smooth, Reproducible Plunger Glide

A prefilled syringe only works if its rubber stopper slides down the barrel with a low, consistent force — low enough for a patient's thumb, or an autoinjector spring, to actuate reliably. Bare glass or polymer against bare rubber does not glide; it sticks and slips. Silicone oil, sprayed onto the inner barrel wall during manufacturing, is the thin lubricant film that makes self-administered injectables mechanically possible — but it is also the single largest driver of particle formation risk in biologic drug products.

• 100–400: Typical silicone load (µg per 1 mL syringe barrel)
• <10 N: Target break-loose force (to initiate plunger movement)
• <15–20 N: Target glide force (sustained, patient-actuable)
• >6 B: Prefilled syringes filled/yr (global biologics + vaccines)

Break-loose force, glide force, and why they must be low and consistent

Every prefilled syringe has two mechanical specifications that quality control must hit on every single unit:

• Break-loose force: the force needed to start the stopper moving from its resting position after storage. Rubber stoppers can "stick" to glass through mechanical interlock and adhesion over time; too much break-loose force means a patient cannot start the injection, or an autoinjector spring stalls. • Glide force (dynamic/extrusion force): the sustained force needed to keep the stopper moving once it starts. Too high, and injection is slow, painful, or incomplete; too variable, and dose delivery becomes unpredictable, particularly in spring-driven autoinjectors and wearable pump-syringes that supply a fixed force budget.

Both are governed almost entirely by the coefficient of friction between the rubber stopper and the barrel wall — and silicone oil is what lowers that coefficient into an acceptable range. Without it, break-loose forces can exceed 30–50 N, far beyond what a thumb or a compact spring mechanism can deliver, especially for the more viscous formulations increasingly used for high-concentration monoclonal antibodies.

As biologic formulations trend toward higher concentrations (100–200 mg/mL) to reduce injection volume, formulation viscosity rises sharply — which raises the glide-force budget even further. This is pushing device engineers toward tighter silicone control and, increasingly, silicone-free lubrication strategies rather than simply adding more oil.

The siliconization process — spray-on deposition and process control

Two industrial siliconization methods dominate current manufacturing:

• Spray-on siliconization: an atomized silicone oil emulsion (or pure oil) is sprayed through a nozzle traveling the length of the barrel interior as it rotates, depositing a thin, relatively uniform film — typically hundreds of nanometers thick, amounting to 100–400 µg of oil per 1 mL syringe. This is the dominant method for high-speed syringe filling lines. • Dip/immersion siliconization: barrels are dipped in a silicone bath and drained; simpler but less uniform, largely displaced by spray methods for parenteral-grade syringes.

Critical process parameters include nozzle traverse speed, oil viscosity, spray pressure, and drying/curing time — each tightly controlled because both too little silicone (functional failure, stopper sticks) and too much silicone (excess free oil available to migrate into the drug product) are undesirable. Modern siliconization lines use camera-based or laser-reflectometry in-process controls to verify film thickness and uniformity on every barrel before it ever reaches the filling suite.

Filling the Syringe — First Contact Between Biologic and Silicone Interface

The moment a protein formulation is aseptically filled into a siliconized barrel, the drug product acquires a permanent new neighbor: a hydrophobic oil film lining every square millimeter of its container. From this point through the entire shelf life of the product — often 24–36 months at 2–8°C — the protein solution sits in continuous contact with silicone, air (in the small headspace), and the container surfaces themselves, each of which is a distinct interface capable of destabilizing a therapeutic protein.

• 0.3–2.25 mL: Typical fill volume (subcutaneous biologic dose range)
• PS20 / PS80: Common surfactant (0.01–0.04% w/v, interface protection)
• 3+: Interfaces present (liquid–silicone, liquid–air, liquid–glass)
• 24–36 mo: Real-time stability program (at 2–8 °C label storage)

Formulation design as the first line of defense

Because interfacial stress cannot be fully eliminated from a prefilled syringe, formulation scientists build protection directly into the drug product before it ever meets the silicone layer:

• Non-ionic surfactants (polysorbate 20 or 80, and increasingly poloxamer 188) are added at low concentration (0.01–0.04% w/v). These molecules preferentially occupy hydrophobic interfaces — air-liquid, silicone-liquid — competing with the much larger, slower-diffusing protein molecules for interfacial "real estate," and substantially reducing the amount of protein that adsorbs and unfolds. • Ionic strength, pH, and buffer selection are tuned to keep the protein in its most conformationally stable state, since a marginally stable protein is far more prone to interfacial unfolding than a robustly folded one. • Overfill and headspace are minimized by design, since a smaller air-liquid interface and less headspace agitation during shipping both reduce one major source of interfacial stress.

None of these strategies eliminate the silicone interface itself — they only make the protein more resilient in its presence.

The multi-interface problem unique to prefilled syringes

A vial with a rubber stopper only inserted at the point of use exposes a biologic to far fewer permanent interfaces than a prefilled syringe does. Inside a prefilled syringe, the drug product simultaneously touches:

• Liquid–silicone interface: the entire cylindrical inner wall, continuously, for the full shelf life • Liquid–air interface: the meniscus at the small headspace bubble intentionally left for thermal expansion • Liquid–elastomer interface: the tip cap or stopper face, itself sometimes also siliconized or fluoropolymer-laminated • Liquid–glass or liquid–polymer interface: any area of the barrel wall not fully coated by the silicone film

Each interface can independently nucleate protein unfolding and aggregation, and their effects are additive over time — which is why prefilled syringe formulations generally require more extensive forced-degradation and real-time stability testing than the equivalent vial presentation of the same molecule.

Silicone Oil Migration — From Thin Film to Free-Floating Microdroplets

A freshly sprayed silicone film is not thermodynamically stable sitting under an aqueous protein solution. Over weeks to months of storage — and dramatically faster under the vibration, shock, and temperature cycling of cold-chain shipping — the continuous oil layer de-wets from the barrel wall through thin-film instability, budding off as discrete microdroplets that disperse into the bulk drug solution, where they become new mobile surfaces for protein to find.

• 0.1–50 µm: Droplet size range (submicron to subvisible)
• ASTM D4169: Shipping test standard (simulated distribution vibration)
• Agitation ×: Droplet growth driver (time and temperature cycling)
• Variable: Free oil vs bound oil (process-dependent split)

The physics of oil migration: thin-film instability and mechanical shear

Silicone oil films de-wet and disperse through several coupled mechanisms:

• Thin-film (Rayleigh-Plateau-like) instability: a continuous oil film under an aqueous phase is metastable; small perturbations grow over time, causing the film to rupture into isolated droplets that minimize total interfacial energy — a slow process at rest but dramatically accelerated by any mechanical disturbance. • Agitation-induced shear: shipping vibration, road transport shock, pneumatic tube transport within hospitals, and even repeated handling by patients or caregivers all impart shear forces at the wall that tear droplets free from the film far faster than passive de-wetting alone. • Temperature cycling: freeze-thaw excursions and routine cold-chain temperature variation change oil viscosity and the wetting behavior of the film, each cycle providing another opportunity for droplets to detach. • Higher initial silicone load simply provides more oil available to migrate — syringes siliconized at the low end of the functional range consistently show fewer free droplets over time than heavily siliconized units, even though both may pass initial glide-force testing.

Once free, droplets are buoyant and diffusive, redistributing through the fill volume and dramatically increasing the total oil-water interfacial surface area available for protein to adsorb onto — a single 300 µg film converted into micron-scale droplets can present orders of magnitude more surface area than it did as a continuous coat.

Detecting droplet formation before it becomes a particle problem

Silicone droplets themselves are colorless, roughly spherical, and refractive-index-mismatched from the aqueous phase — properties that make them readily countable, but also easy to mistake for genuine protein particles, by light obscuration and micro-flow imaging instruments. Shipping-simulation studies (controlled vibration and drop-testing per ASTM D4169, combined with accelerated and real-time thermal cycling) are run specifically to quantify how fast a given container-closure and formulation combination sheds droplets under realistic distribution stress, well before subvisible particle counts approach any regulatory limit.

From Droplet Surface to Visible Particle — How Proteins Unfold and Aggregate at the Silicone Interface

A silicone oil droplet suspended in a protein solution behaves, from the protein's point of view, almost exactly like an air bubble: both present a hydrophobic surface against an aqueous phase, and both are highly effective at denaturing adsorbed protein. Once enough unfolded protein accumulates and cross-links at enough droplet surfaces, the result is no longer a benign silicone droplet — it is a proteinaceous, silicone-containing particle, potentially large enough to see with the naked eye.

• Seconds–min: Adsorption timescale (initial interfacial capture)
• 2–100+ µm: Particle size at risk (subvisible through visible)
• ≤6000: USP <788> limit (≥10 µm) (particles per container)
• ≤600: USP <788> limit (≥25 µm) (particles per container)

The interfacial unfolding mechanism, step by step

Interface-driven particle formation proceeds through a well-characterized sequence:

1. Adsorption: protein molecules diffuse to the silicone-water interface and adsorb, driven by the thermodynamic favorability of burying hydrophobic residues away from water at the oil surface. 2. Conformational unfolding: once adsorbed, the protein's tertiary structure is no longer stabilized by its native aqueous environment on the side facing the oil. Domains partially unfold to maximize favorable hydrophobic contact with the interface, exposing residues and structural motifs normally buried in the folded core. 3. Surface crowding and lateral interaction: as more protein adsorbs, the interface becomes crowded. Unfolded, surface-exposed hydrophobic patches on neighboring molecules interact with each other rather than the interface, nucleating irreversible protein-protein aggregates directly at the droplet surface. 4. Particle growth and desorption: aggregates can grow large enough to detach from the droplet as free particles, or remain droplet-associated as a proteinaceous shell — either way, the population of subvisible and eventually visible particles in the syringe increases with time, agitation, and available interfacial area.

Surfactants slow this cascade by outcompeting protein for interfacial sites, but they cannot fully prevent it, especially once free silicone droplet surface area is large relative to the surfactant reservoir.

Subvisible and visible particles in an injectable biologic are not just a cosmetic defect — protein aggregates are a recognized immunogenicity risk factor. Repetitive, ordered protein epitopes on an aggregate surface can cross-link B-cell receptors far more effectively than monomer, potentially triggering anti-drug antibody responses that can neutralize efficacy or, rarely, cause hypersensitivity reactions. This is why regulators treat particle burden in injectables as a patient-safety attribute, not merely an aesthetic one.

Why this is a defined regulatory concern for injectable products

Compendial standards set hard numeric limits on particulate matter in injectable products. USP <788> (and the equivalent Ph. Eur. 2.9.19) requires that small-volume parenterals contain no more than 6000 particles per container ≥10 µm and 600 particles per container ≥25 µm, measured by light obscuration (with micro-flow imaging as an orthogonal or confirmatory method). Visible particles are addressed separately under USP <790>/<1790> — essentially, if a trained inspector can see it under defined lighting, the unit is rejected outright, regardless of subvisible counts. Because silicone-induced protein particles can straddle both the subvisible and visible size ranges depending on how far the adsorption-aggregation cascade has progressed, they are scrutinized across the entire particle characterization program for a prefilled syringe product, from early formulation development through end-of-shelf-life stability testing.

Engineering Around the Problem — Alternative Coatings and Analytical Particle Characterization

The pharmaceutical industry has spent two decades converging on a toolkit that keeps the mechanical benefits of silicone lubrication while sharply reducing the free oil available to migrate and interact with a biologic. That engineering effort is paired with an analytical program — light obscuration and micro-flow imaging chief among the methods — that must reliably detect and characterize particles at every stage from process development through commercial release and ongoing stability.

• ~50–80%: Baked-on silicone reduction (less free/migratable oil vs. sprayed)
• Covalently bound: Cross-linked silicone (to barrel surface, minimal migration)
• ~1 µm: MFI detection floor (vs. ~2 µm for light obscuration)
• Growing: Silicone-free barrel adoption (fluoropolymer-coated components)

Mitigation technologies across the container-closure spectrum

Manufacturers now select from a spectrum of siliconization strategies, trading off lubricity, cost, and particle risk:

• Baked-on (cured) silicone: after spray application, the barrel is heat-treated to partially cross-link and adhere the silicone film to the glass surface far more strongly than an as-sprayed film. This dramatically reduces the fraction of "free" oil available to bud off as droplets, while still providing adequate glide performance — now a common standard for high-value biologics. • Cross-linked silicone emulsions: proprietary silicone formulations that chemically bond to the barrel surface, going a step further than baking alone to minimize migratable oil, at some additional process cost and complexity. • Ultra-low-silicone, tightly controlled spray processes: rather than changing the oil chemistry, some manufacturers simply drive the applied silicone load down to the minimum functionally required amount, verified barrel-by-barrel with in-line optical inspection, accepting a narrower process window in exchange for lower particle risk. • Silicone-free container systems: barrels and, critically, plunger stoppers coated with an inert fluoropolymer film (e.g., ETFE-type laminates) instead of silicone oil. These eliminate the migratable-oil risk entirely, at the cost of typically higher and sometimes less consistent glide/break-loose forces, and are increasingly paired with specially engineered stopper geometries or coatings to close that gap for autoinjector-compatible products.

Analytical characterization — light obscuration and micro-flow imaging

Confirming that a mitigation strategy actually works requires orthogonal analytical methods, because no single technique sees the whole particle population correctly:

• Light obscuration (USP <788>): a light beam is passed through the sample stream, and particles are sized by how much light they block as they pass. It is the required compendial method for regulatory particle-count release testing, fast and well standardized, but it undercounts translucent, low-refractive-index-contrast particles — including many proteinaceous aggregates that are nearly index-matched to the surrounding buffer — and cannot distinguish a silicone droplet from a protein particle. • Micro-flow imaging (MFI) and other flow-imaging microscopy methods: each particle passing through a flow cell is photographed, capturing not just a count and size but a morphology — silicone droplets image as smooth, translucent spheres, while proteinaceous aggregates typically image as irregular, more opaque, non-spherical shapes. This morphological discrimination is exactly what is needed to separate "benign silicone droplet" from "protein particle of clinical concern," and MFI can detect somewhat smaller particles (down to roughly 1 µm) than light obscuration.

Because the two methods have complementary blind spots, a rigorous particle characterization program for a prefilled syringe biologic runs both — light obscuration to satisfy the compendial release specification, and MFI (often supplemented by manual visible-particle inspection and, in investigational work, techniques like Raman microspectroscopy) to understand what the particles actually are and to guide formulation and container-closure decisions long before a product reaches its regulatory filing.

No single particle-counting technology is sufficient on its own. A robust control strategy pairs compendial light obscuration for regulatory compliance with morphology-resolving imaging methods like MFI to correctly attribute particles to their source — silicone droplet, protein aggregate, or extrinsic contaminant — because the appropriate corrective action is completely different for each.